These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25479802)

  • 1. Absolute assignment of breast cancer intrinsic molecular subtype.
    Paquet ER; Hallett MT
    J Natl Cancer Inst; 2015 Jan; 107(1):357. PubMed ID: 25479802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in projecting clustering results across gene expression-profiling datasets.
    Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
    Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
    Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Which biomarkers can we use?].
    Nogi H; Uchida K; Kobayashi T
    Nihon Rinsho; 2012 May; 70(5):816-20. PubMed ID: 22620006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
    Lee DS; Kim SH; Suh YJ; Kim S; Kim HK; Shim BY
    Jpn J Clin Oncol; 2011 Jul; 41(7):854-66. PubMed ID: 21719749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer.
    Zhang M; Liu HX; Teng XD; Wang HB; Cui J; Jia SS; Gu XY; Li ZG
    Ultrastruct Pathol; 2012 Dec; 36(6):381-6. PubMed ID: 23216236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making breast cancer molecular subtypes robust?
    Staaf J; Ringnér M
    J Natl Cancer Inst; 2015 Jan; 107(1):386. PubMed ID: 25479803
    [No Abstract]   [Full Text] [Related]  

  • 11. Is gene array testing to be considered routine now?
    Paik S
    Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subtyping for clinically defined breast cancer subgroups.
    Zhao X; Rødland EA; Tibshirani R; Plevritis S
    Breast Cancer Res; 2015 Feb; 17(1):29. PubMed ID: 25849221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Triple-negative breast cancer--towards a new entity].
    Miron L; Marinca A; Marinca M; Miron I
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):51-8. PubMed ID: 18677903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiles and prognostic markers for primary breast cancer.
    Wang Y; Klijn J; Zhang Y; Atkins D; Foekens J
    Methods Mol Biol; 2007; 377():131-8. PubMed ID: 17634613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of HER-2/neu overexpression among Iranian women with breast cancer: true or false?
    Saatee S; Afrakhteh M; Sadrolhefazi B
    Breast J; 2006; 12(5):499-501. PubMed ID: 16958978
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.